Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler

Piper Sandler lowered the firm’s price target on Keros Therapeutics (KROS) to $15 from $40 and keeps an Overweight rating on the shares. The company announced its decision to stop dosing within the 1.5 mg/kg and placebo arms of cibotercept’s ongoing Phase II TROPOS trial in pulmonary arterial hypertension following additional pericardial effusion events, along with an overall risk-benefit analysis, the analyst tells investors in a research note. The firm says this follows the decision last month to stop dosing in the 3.0 and 4.5 mg/kg arms for that same reason. Moving forward, KER-065 now becomes the company’s primary wholly-owned clinical stage asset, says Piper.